Form 4: Xenon Pharmaceuticals CFO Reports Stock Transaction
Insider Transaction (Form 4)
Thomas Patrick Kelly, Chief Financial Officer of Xenon Pharmaceuticals Inc., reported multiple transactions in common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 7,500 Common Shares on October 15, 2026; holds 22,500 after (Direct).
- Option exercise/conversion: disposed of 7,500 Restricted Share Units on October 15, 2026; holds 22,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Thomas Patrick Kelly — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Shares | 7,500 | — | — | 22,500 |
| 2026-10-15 | Option exercise/conversion | Restricted Share Units | 7,500 | — | — | 22,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (7,500 shares) |
| 2026-10-15 | Option exercise/conversion (7,500 shares) |
Keywords
insider transaction, Form 4, XENE, Xenon Pharmaceuticals Inc., neutral, Thomas Patrick Kelly
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.